株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨折:パイプライン製品の分析

Bone Fracture - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 271824
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.53円で換算しております。
骨折:パイプライン製品の分析 Bone Fracture - Pipeline Review, H2 2019
出版日: 2019年11月18日 ページ情報: 英文 75 Pages
概要

骨折とは、骨組織の強度を上回るような衝撃が加えられて、骨が折れてしまうという状況を指します。主な症状・徴候として、骨折した部位が腫れあがる、紫斑が現れる、折れた腕・骨が変形する、損傷した部分の機能が失われる、複雑骨折の場合は骨が皮膚を突き破って出てくる、といったことが挙げられます。

当レポートでは、世界各国での骨折治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

骨折の概要

治療薬の開発

  • 骨折向けパイプライン製品:概要
  • 骨折向けパイプライン製品:比較分析

各企業で開発中の骨折治療薬

大学/研究機関で研究中の骨折治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

骨折治療薬:開発中の製品の一覧(企業別)

骨折治療薬:研究中の製品の一覧(大学/研究機関別)

骨折治療薬の開発に従事している企業

  • Arcarios BV
  • AstraZeneca Plc
  • Biogenomics Limited
  • BiologicsMD, Inc.
  • Biopharm GmbH
  • Bone Therapeutics SA
  • ethris GmbH
  • Juventas Therapeutics, Inc.
  • Kuros Biosciences AG
  • Novartis AG
  • TissueGene, Inc.
  • Viking Therapeutics, Inc.

骨折:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ALLOB
  • AZD-2858
  • bimagrumab
  • BMD-1221
  • Cyndacel-M
  • denosumab biosimilar
  • dibotermin alfa
  • Drugs to Modulate Bone Morphogenetic Protein for Osteoarthritis and Fracture
  • Drugs to Modulate PPAR-Delta for Immunology, Metabolic and Musculoskeletal Disorders
  • Gene Therapy for Bone Fracture
  • JVS-200
  • KAL-436
  • KUR-111
  • KUR-113
  • LWnt-3a
  • Oligonucleotide to Activate BMP-2 for Bone Fracture
  • Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson's Disease
  • Recombinant Protein to Activate TNF-Alpha for Fracture Repair
  • Small Molecules for Immunology, Metabolic and Musculoskeletal Disorders
  • Small Molecules for Immunology, Musculoskeletal and Metabolic Disorders
  • Stem Cell Therapy for Fracture Repair
  • Synthetic Peptide for Osteoporosis and Bone Fracture
  • TG-B
  • VK-5211

骨折治療薬:パイプライン製品の最新動向

骨折治療薬:開発が休止状態の製品

骨折関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(1件)

付録

図表一覧

図表

List of Tables

  • Number of Products under Development for Bone Fracture, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Bone Fracture - Pipeline by Bone Therapeutics SA, H2 2019
  • Bone Fracture - Pipeline by ethris GmbH, H2 2019
  • Bone Fracture - Pipeline by Hemostemix Inc, H2 2019
  • Bone Fracture - Pipeline by Kuros Biosciences AG, H2 2019
  • Bone Fracture - Pipeline by Laboratorios SALVAT SA, H2 2019
  • Bone Fracture - Pipeline by Theragnostic Technologies Inc, H2 2019
  • Bone Fracture - Pipeline by USV Pvt Ltd, H2 2019
  • Bone Fracture - Pipeline by Viking Therapeutics Inc, H2 2019
  • Bone Fracture - Dormant Projects, H2 2019
  • Bone Fracture - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Bone Fracture - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Bone Fracture, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11455IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bone Fracture - Pipeline Review, H2 2019, provides an overview of the Bone Fracture (Musculoskeletal Disorders) pipeline landscape.

Fractures are simply a break in a bone caused by forces that exceed the strength of the osseous tissue in the bone. Signs and symptoms of a fracture include swelling or bruising over a bone, deformity of an arm or leg, loss of function in the injured area and in compound fractures, bone protruding from the skin.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bone Fracture - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bone Fracture (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bone Fracture (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Bone Fracture and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 5 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.

Bone Fracture (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bone Fracture (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bone Fracture (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bone Fracture (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bone Fracture (Musculoskeletal Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bone Fracture (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bone Fracture (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Bone Fracture - Overview
  • Bone Fracture - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Bone Fracture - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Bone Fracture - Companies Involved in Therapeutics Development
    • Bone Therapeutics SA
    • ethris GmbH
    • Hemostemix Inc
    • Kuros Biosciences AG
    • Laboratorios SALVAT SA
    • Theragnostic Technologies Inc
    • USV Pvt Ltd
    • Viking Therapeutics Inc
  • Bone Fracture - Drug Profiles
    • ALLOB - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCP-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Biologic for Burns and Bone Fractures - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Gene Therapy to Activate BMP2 and VEGF for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KUR-111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KUR-113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oligonucleotide to Activate BMP-2 for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RAB-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-008399 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Metabolic and Musculoskeletal Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Musculoskeletal and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SVT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Osteoporosis and Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit GSK3B for Bone Fracture - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TAI-39 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • teriparatide biosimilar - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VK-5211 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Bone Fracture - Dormant Projects
  • Bone Fracture - Discontinued Products
  • Bone Fracture - Product Development Milestones
    • Featured News & Press Releases
      • Oct 02, 2019: Bone Therapeutics to present preclinical data on the osteogenic properties of ALLOB in bone repair at 27th Annual Meeting of the European Orthopaedic Research Society
      • Jun 13, 2019: Bone Therapeutics allogeneic cell therapy product, ALLOB, meets primary endpoints in Phase Iia study in patients undergoing a lumbar spinal fusion procedure
      • Feb 05, 2019: Bone Therapeutics to present at the Annual Meeting of the Orthopaedic Research Society
      • Oct 01, 2018: Viking Therapeutics presents results from phase 2 study of VK5211 in patients recovering from hip fracture in plenary oral presentation at ASBMR 2018 Annual Meeting
      • Sep 14, 2018: Bone Therapeutics announces final results from Phase I/IIA ALLOB delayed-union fracture study
      • Jul 17, 2018: Viking Therapeutics Announces VK5211 Phase 2 Study Results Selected for Plenary Oral Presentation at ASBMR 2018 Annual Meeting
      • Feb 19, 2018: Bone Therapeutics completes patient recruitment for Phase IIA Spinal Fusion study with ALLOB
      • Nov 28, 2017: Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
      • Sep 25, 2017: Viking Therapeutics to Host Key Opinion Leader Event to Discuss Musculoskeletal Therapeutics in Hip Fracture and Other Settings
      • Sep 20, 2017: Bone Therapeutics: announces all patients meet primary endpoint in ALLOB Phase I/IIA delayed-union study interim analysis
      • Sep 14, 2017: Bone Therapeutics: Reports strong interim results from ALLOB Phase IIA spinal fusion study
      • Jul 12, 2017: Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
      • Mar 09, 2017: Bone Therapeutics Completes Recruitment of 16 Patients in ALLOB PHASE I/IIA Delayed-Union Study
      • Oct 05, 2016: Bone Therapeutics reports positive efficacy data for the ALLOB Phase IIA spinal fusion trial
      • Sep 01, 2016: Viking Therapeutics Presents Phase 1 Data and Highlights Ongoing Phase 2 Study of VK5211 at 5th Fragility Fracture Network Global Congress 2016
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer